Polypeptide inhibitor for inhibiting ten corona viruses
A coronavirus and human coronavirus technology, applied in viral peptides, antiviral agents, viruses, etc., can solve problems such as major side effects, capping system effects, etc., and achieve the effects of inhibiting replication, high specificity and application prospects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0040] The features and advantages of the present invention can be further understood through the following detailed description in conjunction with the accompanying drawings. The examples provided are only illustrative of the method of the present invention and do not limit the rest of the present disclosure in any way. [Example 1] Design and verification of polypeptide inhibitors
[0041] 1. Based on the crystal structure of the non-structural protein nsp10 and nsp16 complex of SARS coronavirus as a reference, the analysis and the principle of polypeptide inhibition
[0042] figure 1 Shown is a diagram of the crystal structure of the co-crystal of the nsp10 and nsp16 complex. figure 1 In A, the green one is nsp10, and the light blue one is nsp16. It can be seen that the two interact through the protein surface to form a complex. According to our previous studies, nsp10 promotes the binding of nsp16 to the substrate (viral RNA) and the binding to the substrate SAM, thereby...
Embodiment 2
[0051] [Example 2] The screening process of P21.
[0052] Reagent preparation:
[0053] 10× Reaction Buffer: 500mM Tris-HCl (pH 7.5), 50mM KCl, 10mM MgCl 2 ,10 mM DTT,400units RNase inhibitor,0.01mM SAM
[0054] isotope 3 H substrate: S-adenosyl[methyl-3H]methionine (67.3Ci / mmol, 0.5μCi / μl)
[0055] Viral RNA substrate: m7GpppA-RNA (derived from MERS coronavirus RNA)
[0056] RNA purification filler: activated DEAE-Sephadex TM A-25
[0057] Implementation steps:
[0058] 1. In a 25μl reaction system [50mM Tris-HCl (pH 7.5), 1mM MgCl 2 , 5mM KCl, 1mMDTT, 40units RNase inhibitor, 0.01mM SAM] were added to the purified MERS coronavirus nonstructural proteins nsp16 (3.3μM) and nsp10 (10μM).
[0059] 2. Add peptides P57, P41, P29, P21, P16, P8, P4 with a final concentration of 200 μM to the reaction, and other control groups and mix well.
[0060] 3. Add 0.5μCi S-adenosyl[methyl-3H]methionine (67.3 Ci / mmol, 0.5μCi / μl) to each reaction system and mix well.
[0061] 4. Add...
Embodiment 4
[0082] [Example 4] TCP21 inhibits the methyltransferase activity of ten kinds of coronavirus non-structural proteins nsp16 such as MERS (viral RNA capping system activity)
[0083] Reagent preparation:
[0084] 10× Reaction Buffer: 500mM Tris-HCl (pH 7.5), 50mM KCl, 10mM MgCl 2 ,10 mM DTT,400units RNase inhibitor,0.1mM SAM
[0085] isotope 3 H substrate: S-adenosyl[methyl-3H]methionine (67.3Ci / mmol, 0.5μCi / μl)
[0086] Viral RNA substrate: m7GpppA-RNA (derived from MERS coronavirus RNA)
[0087] RNA purification filler: activated DEAE-Sephadex TM A-25
[0088] Implementation steps:
[0089] 1. In a 25μl reaction system [50mM Tris-HCl (pH 7.5), 1mM MgCl 2 , 5mM KCl, 1mMDTT, 40units RNase inhibitor, 0.01mM SAM] were added to the purified MERS and other ten coronavirus non-structural proteins nsp16 (1.6μM) and nsp10 (9.6μM).
[0090] 2. Add 100 and 200 μM peptide inhibitor TCP21 to the reaction, and other control groups were mixed evenly. The amino acid sequence of TCP21...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com